Clinical trial · Expanded Access
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Treatment Guidelines for Expanded Access of Imvotamab (IGM-2323) in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas From IGM-2323-001
NCT06331832CI-TRIAL-00075413no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Non-Hodgkin Lymphomas | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IGM2323 | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Demonstrated clinical benefit (SD, PR, or CR) on clinical trial protocol IGM-2323-001 * There is no adequate alternative treatment available for the patient. * Provided consent to continue treatment on expanded access program. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to the first dose. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures. * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive. Exclusion Criteria: * History of severe allergic or anaphylactic reactions to mAb (or recombinant antibody related fusion proteins). * Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of investigational product, or indicating patient would unlikely have potential benefit. * Pregnant, breastfeeding, or intending to become pregnant during the program or within 2 months after the final dose of imvotamab. * In the treating physician's judgement, the patient is unlikely to complete all procedures, including follow-up visits, or comply with the requirements for participation. * Vaccination with live virus vaccines during treatment and for 3 months following the last cycle of Imvotamab.
References
Publications (0)
Data not yet available
No reference posted for this study.